Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $12.91 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.